

Polyclonal Anti-Angiopoietin-2, **ANG2**

Catalogue No. PA1005

Lot No. 03A01

Ig type: rabbit IgG

Size: 100µg/vial

Specificity

Human, mouse, rat.

No cross reactivity with other proteins.

Recommended application

Western blot

Immunohistochemistry(P)

Manufactured by

Boster Biological Technology

Optimum Biotech

www.optimumbiotech.com

Tel: (1) 908-458-5358

Fax: (1) 908-382-3285

support@optimumbiotech.com

Immunogen

A synthetic peptide corresponding to a sequence mapping near the C-terminal of human angiopoietin-2, different from the related mouse sequence by two amino acids.

Purity

Immunogen affinity purified.

Application

Western blot

At 1-2µg/ml with the appropriate system to detect ANG2 in cells and tissues.

Immunohistochemistry(P)

At 1-2µg/ml to detect ANG2 in formalin fixed and paraffin embedded tissues. Boiling the sections is required.

Other applications have not been tested.

Optimal dilutions should be determined by end user.

Contents

Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na₂HPO₄, 0.05mg Thimerosal, 0.05mg NaN₃.

Reconstitution

0.2ml of distilled water will yield a concentration of 500µg/ml.

Storage

At -20°C for one year. After reconstitution, at 4°C for one month. It can also be aliquotted and stored frozen at -20°C for longer time.

Relative detection systems

Antibody can be supported by chemiluminescence kit EK1002 in WB, supported by SA1022 in IH(P).

BACKGROUND

Angiopoietin 1 and Angiopoietin 2 are important for development of the endothelium, by regulating tyrosine phosphorylation of the membrane receptor Tie 2. Angiopoietin 2 is only 60% homologous with Angiopoietin 1. Angiopoietin-2 is a naturally occurring antagonist of angiopoietin-1 that competes for binding to the TIE2 receptor and blocks ANGPT1-induced TIE2 autophosphorylation. Angiopoietin 1 binding to Tie 2 causes phosphorylation of the receptor. Angiopoietin 2 competes for this binding, and thus blocks receptor phosphorylation. Angiopoietin 2 expression occurs at sites of vascular remodelling: dorsal aorta and major aortic branches, ovary, placenta and uterus.

REFERENCE

1. Kim, I.; Kim, J.-H.; Ryu, Y. S.; Jung, S. H.; Nah, J. J.; Koh, G. Y. : Characterization and expression of a novel alternatively spliced human angiopoietin-2. *J. Biol. Chem.* 275: 18550-18556, 2000.
2. Maisonpierre, P. C.; Suri, C.; Jones, P. F.; Bartunkova, S.; Wiegand, S. J.; Radziejewski, C.; Compton, D.; McClain, J.; Aldrich, T. H.; Papadopoulos, N.; Daly, T. J.; Davis, S.; Sato, T. N.; Yancopoulos, G. D. : Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. *Science* 277: 55-60, 1997.
3. Ward, E. G.; Grosios, K.; Markham, A. F.; Jones, P. F. : Genomic structures of the human angiopoietins show polymorphism in angiopoietin-2. *Cytogenet. Cell Genet.* 94: 147-154, 2001.